IHC Test for HER-2 Positive Breast Cancer: Uses, Procedure, Accuracy

If breast cancer paperwork had a personality, the HER2 section would be the part that walks in late, flips the table,
and somehow decides which treatments get invited to the party. The good news: we have a solid way to measure it.
One of the most common first steps is the IHC test (immunohistochemistry), a lab method that checks how much
HER2 protein is showing up on the surface of tumor cells.

This guide breaks down what the HER2 IHC test is, why it’s used, what actually happens to your tissue sample,
how results are scored (the famous 0–3+ scale), and what “accuracy” really means in the real world (hint:
it’s not just a single percentagebiology loves nuance).

HER2 in Plain English (With a Tiny Bit of Science)

HER2 (human epidermal growth factor receptor 2) is a protein that sits on the surface of some breast cancer cells.
When there’s too much HER2 signaling, the cancer can grow and spread faster. Cancers with true HER2 overexpression or
HER2 gene amplification are often called HER2-positive, and they may respond well to therapies that target HER2.

But not every tumor fits neatly into “positive” vs. “negative.” Modern care also pays attention to
HER2-low (and, in some contexts, “ultralow”), because certain newer treatments may help even when HER2 is not amplified.
That’s one reason the exact IHC score mattersnot just the final label.

What Is the HER2 IHC Test?

Immunohistochemistry (IHC) is a staining method used by pathology labs. A special antibody (think: a
highly trained “sniffer dog”) binds to the HER2 protein on tumor cells. A detection system then makes that binding visible
under the microscope, usually as membrane staining around the cell edges.

A pathologist scores the intensity and pattern of staining on a standardized scale:
0, 1+, 2+, or 3+. That score guides the next stepespecially whether you need confirmatory testing with
ISH/FISH (tests that look for HER2 gene amplification).

Uses: Why the HER2 IHC Test Matters So Much

The HER2 IHC test isn’t ordered because doctors enjoy extra paperwork (they do not). It’s ordered because it answers
high-impact questions:

• Treatment selection: HER2 status helps determine eligibility for HER2-targeted therapies (especially when HER2 is truly positive).
• Risk and behavior clues: HER2-positive cancers can behave more aggressively, but also may respond dramatically to targeted treatment.
• Clarifying “borderline” cases: If IHC is 2+, the result is typically considered equivocal and triggers reflex testing (ISH/FISH).
• Identifying HER2-low: Some cancers that are not HER2-amplified can still be categorized as HER2-low based on IHC scoring, which may matter for certain therapies.
• Retesting at recurrence or metastasis: HER2 expression can differ between the original tumor and a later recurrence/metastasis, so clinicians may recheck it.
• Clinical trials: Many studies require a specific HER2 category, and the IHC score can be part of the eligibility criteria.

Procedure: What Actually Happens During HER2 IHC Testing

Patients often hear “we’re running an IHC test” and picture a dramatic machine with blinking lights. In reality,
it’s a carefully controlled lab workflow that turns a tiny tissue sample into a scored result.

1) Tissue collection (a biopsy or surgery)

The IHC test is performed on tumor tissue, usually from a core needle biopsy (common at diagnosis) or from a
surgical specimen (lumpectomy/mastectomy). The pathologist selects representative tumor areas for testing.

2) Fixation (the “preserve it correctly” step)

Once tissue is removed, it needs to be preserved quickly and properly to prevent protein degradation and staining artifacts.
Typically, tissue is placed into 10% neutral buffered formalin. Timing matters:
too short or too long fixation can alter staining and affect interpretation.

Labs also try to minimize cold ischemia timethe time between tissue removal and fixationbecause delays can
change how well proteins stain.

3) Processing and embedding (turning tissue into a “block”)

The fixed tissue is processed through dehydrating steps and embedded in paraffin wax to create a firm block.
This block allows very thin slices to be cut consistently.

4) Sectioning (slicing tissue paper-thin)

A lab professional cuts thin sections (often just a few micrometers thick) and places them on microscope slides.
Think “tissue lasagna,” but with fewer calories and more medical significance.

5) Staining with HER2 antibodies

The slide is treated so the HER2 antibody can bind to HER2 proteins on tumor cell membranes. A detection system
makes the binding visible. The slide is counterstained so the cells and tissue architecture are easy to evaluate.

6) Interpretation by a pathologist

A pathologist examines the staining pattern, intensity, and percentage of tumor cells stained and assigns the
HER2 IHC score (0, 1+, 2+, 3+). Some labs also use digital pathology tools for consistency, but expert interpretation
remains central.

Understanding IHC Scores: 0 vs 1+ vs 2+ vs 3+

Here’s the part that gets quoted in pathology reports, discussed in tumor boards, and Googled at 2:00 a.m.
(If that’s you: please hydrate and try not to let the internet drive the car.)

Two key takeaways:
(1) IHC is a protein test (what’s on the cell surface), while ISH/FISH is a gene test (what’s happening at the DNA level).
(2) IHC 2+ is the classic “we need more information” category.

What Happens If the Result Is 2+ (Equivocal)?

A 2+ result usually triggers reflex testing with ISH (in situ hybridization), often called FISH
when fluorescence is used. ISH/FISH looks for HER2 gene amplificationextra copies of the HER2 gene inside tumor cells.

Why the extra step? Because a tumor can have borderline protein expression on IHC for several reasons:
technical factors, biologic variation, or tumor heterogeneity (different areas of the tumor behaving differently).
ISH helps resolve whether the tumor is truly HER2-driven.

• IHC 2+ + ISH amplified: typically considered HER2-positive.
• IHC 2+ + ISH not amplified: typically considered HER2-negative for classic HER2-positive therapy decisions, but may fall into HER2-low territory depending on context.

Accuracy: How Reliable Is the HER2 IHC Test?

“Accuracy” sounds like it should be one clean number, like “98% accurate.” In HER2 testing, it’s more helpful to think in layers:
pre-analytic (how the tissue is handled), analytic (how the staining is performed),
and post-analytic (how it’s interpreted).

Where HER2 IHC is strongest

The test is generally most consistent at the extremes:
truly negative cases (clear 0) and truly positive cases (clear 3+). When staining patterns are obvious, interpretation is more reproducible.

Where things get tricky

The “gray zones” are where variability can creep in:

• 0 vs 1+: Differentiating “no staining” from “very faint/incomplete staining” can be subtleand this has become more relevant with HER2-low discussions.
• 1+ vs 2+: Borderline intensity and completeness can lead to differences between observers and labs.
• Tumor heterogeneity: Some tumors show mixed areasone region may stain stronger than another, making scoring more complex.
• Specimen factors: Small biopsies, crushed tissue, necrosis, or prior treatment can affect staining quality.

How labs protect accuracy

High-quality labs follow standardized guidance, validate their assays, run controls, and participate in proficiency programs.
Many also use reflex ISH for equivocal IHC results to reduce the chance of misclassification.

If results don’t fit the clinical pictureor if the sample quality is questionableclinicians may recommend repeat testing on
another tissue block or on a newer biopsy.

Common Reasons for False Negatives or False Positives

Most “errors” in HER2 IHC aren’t dramatic lab mistakes; they’re usually the result of small distortions introduced along the journey
from patient to microscope.

False negatives (HER2 looks lower than it truly is)

• Under-fixation or delayed fixation (proteins degrade or stain poorly).
• Over-fixation or suboptimal processing affecting antigen detection.
• Sampling issues (the tested area isn’t representative of the tumor).
• Technical variation in staining platforms, reagents, or validation thresholds.

False positives (HER2 looks higher than it truly is)

• Non-specific staining or background artifact that mimics membrane staining.
• Interpretation pitfalls when staining is incomplete, uneven, or present in non-tumor cells.
• Edge effects or technical artifacts that exaggerate intensity.

Bottom line: a good lab plus guideline-driven interpretation dramatically lowers the risk, and equivocal cases have a built-in safety net:
confirm with ISH/FISH.

How Long Do Results Take?

Turnaround time varies by facility, but many centers can report HER2 IHC within a few days after the lab receives the tissue.
If reflex ISH/FISH is needed (often after a 2+ result), it can add additional time.

If you’re waiting and it feels like time is moving in slow-motion: you’re not imagining it. Medical waiting time is measured in
a special unit called the panic-hour, where one day equals three years.

What Should You Ask Your Care Team?

• What is my exact HER2 IHC score (0, 1+, 2+, or 3+)?
• If it’s 2+, was ISH/FISH doneand what was the result?
• Is there any concern about sample quality (fixation, size, crush artifact, low tumor content)?
• If my cancer returns or spreads, would you recommend retesting HER2 on the new site?
• How does my HER2 status interact with other markers (ER/PR, Ki-67, etc.) in my treatment plan?

FAQ: Quick Answers Without the Panic Scroll

Is the IHC test a blood test?

No. HER2 IHC is performed on tumor tissue (biopsy or surgical specimen), not blood.

Does “HER2 positive” always mean worse prognosis?

Historically, HER2-positive cancers were associated with more aggressive behavior. But targeted therapies have changed outcomes dramatically.
Prognosis depends on stage, overall tumor biology, and response to therapynot HER2 alone.

If I’m HER2-negative, does HER2 still matter?

It can. Some HER2-negative cancers may be classified as HER2-low based on IHC scoring (often 1+ or 2+ with ISH-negative),
which may influence treatment options in certain settings.

Can my HER2 status change over time?

Yes, it canespecially between the primary tumor and a recurrence/metastasis. That’s why retesting may be recommended in some situations.

Conclusion

The HER2 IHC test is one of the most important tools for classifying breast cancer because it helps guide treatment decisions,
especially around HER2-targeted therapies. The process looks simple on paperstain, score, reportbut the reliability depends on careful
tissue handling, validated lab methods, and expert interpretation.

The core logic is reassuringly straightforward:
3+ is generally HER2-positive, 0–1+ is generally HER2-negative (with increasing attention to HER2-low),
and 2+ is the “double-check with ISH/FISH” category. When you know your exact score and what confirmatory testing was done,
you’re no longer reading a mystery novelyou’re reading a map.

Experiences: The Human Side of HER2 IHC (Extra )

Let’s talk about something pathology reports don’t include: the experience of living through HER2 testing.
For many people, the HER2 IHC result is the first time they realize a biopsy isn’t just “yes/no cancer”it’s also a deep dive into
what kind of cancer and how it behaves. That realization can feel empowering… and also like being handed a syllabus you never signed up for.

A very common experience is result whiplash. Someone hears, “Your HER2 is 2+,” and their brain immediately fills in the blank:
“So… positive?” Then they learn 2+ is equivocal and needs ISH/FISH, which sounds like the lab is saying, “We’re not sure, please hold.”
In reality, that “hold” is a quality-control feature. It’s the system refusing to guess when the stakes are high. Still, emotionally,
waiting for the reflex test can feel like staring at a loading screen for your life plan.

Another frequent experience is confusion about numbers. People will say, “I’m HER2 1+, does that mean I’m ‘a little positive’?”
That’s an understandable interpretationbut clinically, 0 and 1+ have traditionally been treated as HER2-negative for classic HER2-targeted
therapy decisions. At the same time, with the rise of HER2-low conversations, patients sometimes hear that 1+ “counts” in a different way for
certain treatment options. That can feel like the rules changed mid-game. The best coping strategy is to ask your oncologist to translate your
score into what it means for you right now: eligibility for current treatments, trial options, and retesting plans if things change.

Clinicians and pathologists also describe a very real shift in how they talk about “borderline” staining.
In the past, the main purpose of IHC scoring was to find who was clearly HER2-positive and who wasn’t. Today, there’s more attention to the
difference between “no staining” and “faint staining,” because it can matter for categorization in specific contexts. Many care teams have adapted
by being more explicit: they document the exact IHC score and explain whether confirmatory ISH was done.
That helps reduce the classic patient experience of receiving a report that feels like it was written in a dialect of English spoken only by microscopes.

Finally, there’s the experience of retesting. When cancer recurs or spreads, some people are surprised to hear,
“We’re going to biopsy this again and recheck HER2.” It can feel frustratinglike you’re repeating a test you already “passed.”
But biologically, tumors can evolve, and metastases can differ from the original tumor. Retesting is often a way to keep treatment options as broad
and accurate as possible, not a sign that someone missed something the first time.

If there’s one emotional truth worth printing in bold: you don’t have to become a HER2 expert overnight.
You just need the right questions, the right explanations, and a care team willing to walk through the logic with youone score at a time.

SEO Tags